Immunome Inc
IMNM
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.87B
Close$
$7.27
58.2% downside
Current Fair Value
58.2% downsideOvervalued by 58.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.87 Billion |
|---|---|
| Enterprise Value | $1.66 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.43 |
| Beta | 2.13 |
| Outstanding Shares | 113,272,931 |
Return
| Return on Equity | -48.43% |
|---|---|
| Return on Assets | -44.98% |
| Return on Invested Capital | -48.23% |
Valuation & Multiples
| P/E Ratio | -7.7 |
|---|---|
| PEG | -11.24 |
| Price to Sales | - |
| Price to Book Ratio | 4.35 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -6.48 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-0.59
Average shareholder expectationRevenue Estimate
$222,222
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.60
Average shareholder expectationRevenue Estimate
$166,667
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 29.16% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 104.99% |
|---|---|
| Total Invested | $117,898▼ 100.00% |
| Investors Holding | 4▼ 207.00% |
ESG Score
No data
About Immunome Inc
2,020 employeesImmunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company's initi...